Abstract

 CADTH recommends that Dupixent should be reimbursed by public drug plans for the treatment of patients aged 6 to younger than 12 years with severe asthma with a type 2/eosinophilic phenotype if certain conditions are met.
 Dupixent should only be covered for patients with severe asthma aged 6 to younger than 12 years with a type 2 or eosinophilic phenotype if their asthma is not controlled despite using medium- or high-dose inhaled corticosteroids (ICSs) and at least 1 additional medication or high-dose ICS alone, and if they have had at least 1 severe asthma exacerbation in the past year.
 Dupixent should only be reimbursed if prescribed by a pediatric respirologist or allergist, patients are managed by physicians with experience treating asthma in pediatric patients, and the price is reduced. Dupixent should not be used with other biologics.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
